SUNPHARMA - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.2
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established between 1,800 ₹ (support level identified by the 200 DMA) and 1,860 ₹ (resistance tied to the 50 DMA). An exit strategy would involve monitoring the RSI; a breach below 32 would trigger a sell signal. Overall, while the recent earnings growth is encouraging, the high valuation warrants caution and necessitates closely observing volume and momentum developments around key support levels.
✅ Positive
The price is currently trading above the 200-day moving average, indicating a prevailing uptrend momentum at this level. Volume remains elevated compared to its one-week average, suggesting continued interest and potential strength in the current move.
⚠️ Limitation
Despite the strong recent profit growth (22.8% QoQ), the extremely high Stock P/E of 138 relative to the industry PE of 34.8 signals a potentially overvalued situation, presenting a risk if momentum falters and the market corrects. Furthermore, the negative MACD signal (-21.0) indicates that bearish momentum is still present within the broader timeframe.
🏭 Industry
The pharmaceutical sector, particularly generic drug manufacturers like Sun Pharma, is currently experiencing a mixed sentiment due to ongoing regulatory scrutiny and pricing pressures, however, the recent merger offer from Taro Pharmaceutical Industries adds a positive layer of catalyst for potential short-term gains.